 Home > Active Ingredient News > Immunology News > JAMA: Active therapeutic drug monitoring (TDM) can improve the rate of disease control during maintenance treatment with infliximab and reduce the risk of deterioration

JAMA: Active therapeutic drug monitoring (TDM) can improve the rate of disease control during maintenance treatment with infliximab and reduce the risk of deterioration

 Last Update: 2021-12-27
 Source: Internet
 Author: User

Tags

standard fridge temperature

41 therapy

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

TNF inhibitors are used in many chronic immune- related diseases, such as rheumatoid arthritis , spondyloarthritis, psoriatic arthritis,Ulcerative colitis , Crohn’s disease, and psoriasis have played an important role in the treatment of TNF inhibitors, but the failure rate of TNF inhibitors is relatively high.
No response to inhibitor treatment, leading to worsening of the condition
.

Active Therapeutic Drug Monitoring (TDM) is an individualized treatment method based on serum drug levels and anti-drug antibodies.

Immune rheumatoid arthritisUlcerative colitis researchers recently investigated the impact of TDM regimens on the prognosis of patients receiving infliximab treatment during maintenance treatment

This randomized, parallel, open clinical trial was carried out in 20 hospitals in Norway and received maintenance treatment of infliximab in 458 patients with rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, ulcerative colitis , and Adult patients with Rohn’s disease or psoriasis were involved, and the patients were randomly divided into TDM group (n=228) or standard treatment group (n=230).
The TDM group carried out regular monitoring of patients’ serum drug levels and anti-drug antibodies and adjusted them Drug dosage and dosing interval
.

The primary endpoint of the study was the 52-week study period without deterioration of continuous disease control, which was defined as switching to another biologic drug, adding immunosuppressive drugs including glucocorticoids, or increasing the dose of infliximab

Ulcerative colitis

The average age of the patients was 44.
8 years, 216 women (49.
8%), and 454 patients completed the study
.

167 patients (73.

Differences in the risk of treatment failure between groups

The difference in the risk of treatment failure between groups The difference in the risk of treatment failure between groups

Studies believe that for patients with chronic immune-related inflammatory diseases receiving maintenance therapy with infliximab, active therapeutic drug monitoring (TDM) can effectively control the disease and reduce the risk of treatment failure

For patients with chronic immune-related inflammatory diseases receiving infliximab maintenance treatment, active therapeutic drug monitoring (TDM) can effectively control the disease and reduce the risk of treatment failure.

Original source:

Silje Watterdal Syversen et al.

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases A Randomized Clinical Trial.
JAMA Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.